GlassScriptPhysician profile
Michelle Satterfield
NPI 1841859303
$2,811.34
in general payments reported to CMS, 2019-2025
24 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.65 · 2022: $277 · 2023: $1,154 · 2024: $872 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,520.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $536.57 | 2022-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $360.82 | 2022-2025 | |
| Novo Nordisk INC | $348.87 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $296.32 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $221.54 | 2021-2025 | Airsupra, Farxiga, Saphnelo |
| Ucb, INC. | $189.81 | 2023-2024 | Cimzia |
| Lilly USA, LLC | $134.81 | 2022-2024 | Mounjaro, Taltz |
| Pfizer INC. | $98.21 | 2022-2025 | |
| Janssen Biotech, INC. | $85.81 | 2023-2024 | Tremfya |
| Merck Sharp & Dohme LLC | $81.63 | 2022-2023 | Verquvo, Steglujan, Steglatro |
| Aurinia Pharma U.S., INC. | $73.58 | 2023-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $50.32 | 2022-2023 | Trelegy Ellipta |
| Mallinckrodt Hospital Products INC. | $48.38 | 2023 | Acthar |
| Astellas Pharma US INC | $44.54 | 2024 | Veozah |
| Exact Sciences Corporation | $39.97 | 2023-2025 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $32.34 | 2023-2025 | Xarelto, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.81 | 2022-2023 | Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $27.68 | 2025 | |
| Genzyme Corporation | $21.13 | 2024 | |
| Abbott Laboratories | $20.13 | 2025 | Cardiomems |
| Organon LLC | $20.06 | 2023 | Hadlima |
| Genentech USA, INC. | $19.49 | 2023 | Actemra |
| Fresenius Kabi USA, LLC | $14.27 | 2023 | Idacio |
| Averitas Pharma INC. | $14.25 | 2023 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Satterfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.